302 related articles for article (PubMed ID: 37897950)
21. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
Front Immunol; 2022; 13():968395. PubMed ID: 36059451
[TBL] [Abstract][Full Text] [Related]
22. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
23. A chimeric antigen receptor-based cellular safeguard mechanism for selective
Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
[TBL] [Abstract][Full Text] [Related]
24. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety.
Maharshi V; Diksha D; Gupta P
Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor Design Today and Tomorrow.
Boucher JC; Davila ML
Cancer J; 2021 Mar-Apr 01; 27(2):92-97. PubMed ID: 33750067
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells therapy in solid tumors.
Rababah F; Alabduh T; Awawdeh A; Shatnawi T; Al-Shdaifat M; Ibdah E; Shatnawi S; AbuZetun Y; Helaly AM; Ghorab DS
Clin Transl Oncol; 2023 Aug; 25(8):2279-2296. PubMed ID: 36853399
[TBL] [Abstract][Full Text] [Related]
28. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.
Lu L; Xie M; Yang B; Zhao WB; Cao J
Sci Adv; 2024 Feb; 10(8):eadj6251. PubMed ID: 38394207
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
31. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
32. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
33. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
34. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y; Rezvani K; Rafei H
Immunol Rev; 2023 Nov; 320(1):217-235. PubMed ID: 37548050
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
37. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T-cell therapy in acute myeloid leukemia.
Koedam J; Wermke M; Ehninger A; Cartellieri M; Ehninger G
Curr Opin Hematol; 2022 Mar; 29(2):74-83. PubMed ID: 35013048
[TBL] [Abstract][Full Text] [Related]
39. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
40. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
